161 related articles for article (PubMed ID: 19298100)
1. Medicare Part D coverage gap and diabetes beneficiaries.
Schmittdiel JA; Ettner SL; Fung V; Huang J; Turk N; Quiter ES; Swain BE; Hsu JT; Mangione CM
Am J Manag Care; 2009 Mar; 15(3):189-93. PubMed ID: 19298100
[TBL] [Abstract][Full Text] [Related]
2. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes.
Fung V; Mangione CM; Huang J; Turk N; Quiter ES; Schmittdiel JA; Hsu J
Health Serv Res; 2010 Apr; 45(2):355-75. PubMed ID: 20050931
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
4. Beneficiaries with cardiovascular disease and thePart D coverage gap.
Polinski JM; Shrank WH; Glynn RJ; Huskamp HA; Roebuck MC; Schneeweiss S
Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):387-95. PubMed ID: 22511746
[TBL] [Abstract][Full Text] [Related]
5. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
6. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
Tseng CW; Brook RH; Keeler E; Steers WN; Mangione CM
JAMA; 2004 Aug; 292(8):952-60. PubMed ID: 15328327
[TBL] [Abstract][Full Text] [Related]
7. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
8. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
[TBL] [Abstract][Full Text] [Related]
9. Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan.
Nair KV; Frech-Tamas F; Jan S; Wolfe P; Allen RR; Saseen JJ
J Health Care Finance; 2011; 38(2):38-53. PubMed ID: 22372031
[TBL] [Abstract][Full Text] [Related]
10. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
11. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.
Hsu J; Fung V; Price M; Huang J; Brand R; Hui R; Fireman B; Newhouse JP
JAMA; 2008 Apr; 299(16):1929-36. PubMed ID: 18430912
[TBL] [Abstract][Full Text] [Related]
12. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
13. Medicare Prescription Drug Plan Enrollees Report Less Positive Experiences Than Their Medicare Advantage Counterparts.
Elliott MN; Landon BE; Zaslavsky AM; Edwards C; Orr N; Beckett MK; Mallett J; Cleary PD
Health Aff (Millwood); 2016 Mar; 35(3):456-63. PubMed ID: 26953300
[TBL] [Abstract][Full Text] [Related]
14. Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure.
Gokhale M; Dusetzina SB; Pate V; Chun DS; Buse JB; Stürmer T; Gower EW
Diabetes Care; 2020 Sep; 43(9):2121-2127. PubMed ID: 32641378
[TBL] [Abstract][Full Text] [Related]
15. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
16. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
18. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
19. The Medicare Part D doughnut hole: effect on pharmacy utilization.
Sun SX; Lee KY
Manag Care Interface; 2007 Sep; 20(9):51-5, 59. PubMed ID: 18161394
[TBL] [Abstract][Full Text] [Related]
20. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
